{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:42:48Z","timestamp":1790480568773,"version":"4.1.0"},"reference-count":57,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100013101","name":"National Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Loss of the incretin effect (IE) in type 2 diabetes (T2D) contributes to hyperglycemia and the mechanisms underlying this impairment are unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To quantify the IE impairment in T2D and to investigate the factors associated with it using a meta-analytic approach.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PubMed, Scopus, and Web-of-Science were searched. Studies measuring IE by the gold-standard protocol employing an oral glucose tolerance test (OGTT) and an intravenous glucose infusion at matched glucose levels were selected. We extracted IE, sex, age, body mass index (BMI), and hemoglobin A1c, fasting values, and area under curve (AUC) of glucose, insulin, C-peptide, glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1). In subjects with T2D, we also recorded T2D duration, age at diagnosis, and the percentage of subjects taking antidiabetic medications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The IE weighted mean difference between subjects with T2D and those with normal glucose tolerance (NGT) was \u221227.3% (CI \u201336.5% to \u201318.1%; P\u2005&amp;lt;\u2005.001; I2\u2005=\u200586.6%) and was affected by age (P\u2005&amp;lt;\u2005.005). By meta-regression of combined NGT and T2D data, IE was inversely associated with glucose tolerance (lower IE in T2D), BMI, and fasting GIP (P\u2005&amp;lt;\u2005.05). By meta-regression of T2D studies only, IE was associated with the OGTT glucose dose (P\u2005&amp;lt;\u2005.0001). IE from insulin was larger than IE from C-peptide (weighted mean difference 11.2%, CI 9.2-13.2%; P\u2005&amp;lt;\u2005.0001; I2\u2005=\u200528.1%); the IE difference was inversely associated with glucose tolerance and fasting glucose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The IE impairment in T2D vs NGT is consistent though considerably variable, age being a possible factor affecting the IE difference. Glucose tolerance, BMI, and fasting GIP are independently associated with IE; in subjects with T2D only, the OGTT dose is a significant covariate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgac213","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T18:21:26Z","timestamp":1649528486000},"page":"2092-2100","source":"Crossref","is-referenced-by-count":21,"title":["Loss of the Incretin Effect in Type 2 Diabetes: A Systematic Review and Meta-analysis"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4356-3116","authenticated-orcid":false,"given":"Eleonora","family":"Grespan","sequence":"first","affiliation":[{"name":"C.N.R. Institute of Neuroscience , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6873-4372","authenticated-orcid":false,"given":"Annamaria","family":"Guolo","sequence":"additional","affiliation":[{"name":"Department of Statistical Sciences, University of Padua , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6979-3553","authenticated-orcid":false,"given":"Elza","family":"Muscelli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medical Sciences, State University of Campinas , Campinas , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-1584","authenticated-orcid":false,"given":"Ele","family":"Ferrannini","sequence":"additional","affiliation":[{"name":"C.N.R. Institute of Clinical Physiology , Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1436-5591","authenticated-orcid":false,"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[{"name":"C.N.R. Institute of Neuroscience , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"key":"2022061616000036200_CIT0001","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2022061616000036200_CIT0002","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/jc.2010-2435","article-title":"Impaired regulation of the incretin effect in patients with type 2 diabetes","volume":"96","author":"Bagger","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"2022061616000036200_CIT0003","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2337\/db07-1315","article-title":"Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients","volume":"57","author":"Muscelli","year":"2008","journal-title":"Diabetes."},{"key":"2022061616000036200_CIT0004","author":"Grespan","year":"2022"},{"key":"2022061616000036200_CIT0005","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s00125-018-4633-z","article-title":"Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes","volume":"61","author":"Astiarraga","year":"2018","journal-title":"Diabetologia."},{"key":"2022061616000036200_CIT0006","doi-asserted-by":"crossref","first-page":"E774","DOI":"10.1152\/ajpendo.00496.2015","article-title":"The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?","volume":"310","author":"Aulinger","year":"2016","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"2022061616000036200_CIT0007","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1753-0407.2009.00064.x","article-title":"Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery","volume":"2","author":"Bose","year":"2010","journal-title":"J Diabetes."},{"key":"2022061616000036200_CIT0008","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00592-014-0555-5","article-title":"Alpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes","volume":"51","author":"Calanna","year":"2014","journal-title":"Acta Diabetol."},{"key":"2022061616000036200_CIT0009","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.2337\/db13-1176","article-title":"Limited recovery of \u03b2-cell function after gastric bypass despite clinical diabetes remission","volume":"63","author":"Dutia","year":"2014","journal-title":"Diabetes."},{"key":"2022061616000036200_CIT0010","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s00125-017-4265-8","article-title":"Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect","volume":"60","author":"Foghsgaard","year":"2017","journal-title":"Diabetologia."},{"key":"2022061616000036200_CIT0011","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.2337\/dc20-0445","article-title":"A reduced incretin effect mediated by the rs7903146 variant in the TCF7L2 gene is an early marker of beta-cell dysfunction in obese youth","volume":"43","author":"Galderisi","year":"2020","journal-title":"Diabetes Care."},{"key":"2022061616000036200_CIT0012","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2337\/diabetes.51.4.951","article-title":"Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose","volume":"51","author":"Greenbaum","year":"2002","journal-title":"Diabetes."},{"key":"2022061616000036200_CIT0013","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/joim.12388","article-title":"Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis","volume":"278","author":"Gyldenl\u00f8ve","year":"2015","journal-title":"J Intern Med."},{"key":"2022061616000036200_CIT0014","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1210\/jc.2010-0119","article-title":"Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects","volume":"95","author":"Hansen","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"2022061616000036200_CIT0015","doi-asserted-by":"crossref","first-page":"E832","DOI":"10.1152\/ajpendo.00700.2009","article-title":"Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes","volume":"298","author":"Hare","year":"2010","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"2022061616000036200_CIT0016","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00464-015-4581-3","article-title":"Metabolic consequences of the incorporation of a Roux limb in an omega loop (mini) gastric bypass: evaluation by a glucose tolerance test at mid-term follow-up","volume":"30","author":"Himpens","year":"2016","journal-title":"Surg Endosc."},{"key":"2022061616000036200_CIT0017","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2337\/dc16-1376","article-title":"Glucose metabolism after gastric banding and gastric bypass in individuals with type 2 diabetes: weight loss effect","volume":"40","author":"Holter","year":"2017","journal-title":"Diabetes Care."},{"key":"2022061616000036200_CIT0018","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/ki.2012.460","article-title":"Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease","volume":"83","author":"Idorn","year":"2013","journal-title":"Kidney Int."},{"key":"2022061616000036200_CIT0019","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00125-012-2459-7","article-title":"Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes","volume":"55","author":"Jensen","year":"2012","journal-title":"Diabetologia."},{"key":"2022061616000036200_CIT0020","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/jgh.12981","article-title":"Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis","volume":"30","author":"Junker","year":"2015","journal-title":"J Gastroenterol Hepatol."},{"key":"2022061616000036200_CIT0021","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/joim.12462","article-title":"Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia","volume":"279","author":"Junker","year":"2016","journal-title":"J Intern Med."},{"key":"2022061616000036200_CIT0022","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3346\/jkms.2014.29.3.378","article-title":"Simulation of oral glucose tolerance tests and the corresponding isoglycemic intravenous glucose infusion studies for calculation of the incretin effect","volume":"29","author":"Kim","year":"2014","journal-title":"J Korean Med Sci."},{"key":"2022061616000036200_CIT0023","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2337\/db07-0100","article-title":"Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?","volume":"56","author":"Knop","year":"2007","journal-title":"Diabetes."},{"key":"2022061616000036200_CIT0024","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00125-006-0566-z","article-title":"Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus","volume":"50","author":"Knop","year":"2007","journal-title":"Diabetologia."},{"key":"2022061616000036200_CIT0025","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1463-1326.2011.01549.x","article-title":"Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity","volume":"14","author":"Knop","year":"2012","journal-title":"Diabetes Obes Metab."},{"key":"2022061616000036200_CIT0026","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.regpep.2013.08.002","article-title":"Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus","volume":"186","author":"Kosinski","year":"2013","journal-title":"Regul Pept."},{"key":"2022061616000036200_CIT0027","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2337\/dc06-1549","article-title":"Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes","volume":"30","author":"Laferr\u00e8re","year":"2007","journal-title":"Diabetes Care."},{"key":"2022061616000036200_CIT0028","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1210\/jc.2007-2851","article-title":"Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes","volume":"93","author":"Laferr\u00e8re","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"2022061616000036200_CIT0029","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s11695-014-1344-5","article-title":"Laparoscopic sleeve gastrectomy versus single anastomosis (mini-) gastric bypass for the treatment of type 2 diabetes mellitus: 5-year results of a randomized trial and study of incretin effect","volume":"24","author":"Lee","year":"2014","journal-title":"Obes Surg."},{"key":"2022061616000036200_CIT0030","doi-asserted-by":"crossref","first-page":"E1038","DOI":"10.1152\/ajpendo.00665.2010","article-title":"The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes","volume":"300","author":"Lund","year":"2011","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"2022061616000036200_CIT0031","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/apha.12218","article-title":"The incretin effect does not differ in trained and untrained, young, healthy men","volume":"210","author":"Lund","year":"2014","journal-title":"Acta Physiol (Oxf)."},{"key":"2022061616000036200_CIT0032","doi-asserted-by":"crossref","first-page":"E1144","DOI":"10.1152\/ajpendo.00571.2005","article-title":"Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance","volume":"291","author":"Muscelli","year":"2006","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"2022061616000036200_CIT0033","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab."},{"key":"2022061616000036200_CIT0034","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia."},{"key":"2022061616000036200_CIT0035","first-page":"912","article-title":"Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations","volume":"76","author":"Nauck","year":"1993","journal-title":"J Clin Endocrinol Metab."},{"key":"2022061616000036200_CIT0036","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00572873","article-title":"Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation","volume":"30","author":"Nauck","year":"1993","journal-title":"Acta Diabetol."},{"key":"2022061616000036200_CIT0037","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.regpep.2004.06.020","article-title":"Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes","volume":"122","author":"Nauck","year":"2004","journal-title":"Regul Pept."},{"key":"2022061616000036200_CIT0038","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/dmrr.2441","article-title":"Tumour necrosis factor-alpha infusion produced insulin resistance but no change in the incretin effect in healthy volunteers","volume":"29","author":"Nielsen","year":"2013","journal-title":"Diabetes Metab Res Rev."},{"key":"2022061616000036200_CIT0039","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s13054-015-1118-z","article-title":"The incretin effect in critically ill patients: a case-control study","volume":"19","author":"Nielsen","year":"2015","journal-title":"Crit Care."},{"key":"2022061616000036200_CIT0040","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1152\/japplphysiol.00821.2015","article-title":"The effect of 8 days of strict bed rest on the incretin effect in healthy volunteers","volume":"120","author":"Nielsen","year":"2016","journal-title":"J Appl Physiol (1985)."},{"key":"2022061616000036200_CIT0041","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1210\/jc.2014-4042","article-title":"Recovery of the incretin effect in type 2 diabetic patients after biliopancreatic diversion","volume":"100","author":"Novaes","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"2022061616000036200_CIT0042","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/cen.12167","article-title":"The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes","volume":"80","author":"Oh","year":"2014","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2022061616000036200_CIT0043","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.2337\/db13-1878","article-title":"Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3","volume":"63","author":"\u00d8stoft","year":"2014","journal-title":"Diabetes."},{"key":"2022061616000036200_CIT0044","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/EJE-13-0264","article-title":"Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty","volume":"169","author":"Plamboeck","year":"2013","journal-title":"Eur J Endocrinol."},{"key":"2022061616000036200_CIT0045","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1089\/jwh.2010.2272","article-title":"The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study","volume":"20","author":"Pontikis","year":"2011","journal-title":"J Womens Health (Larchmt)."},{"key":"2022061616000036200_CIT0046","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/EJE-14-0314","article-title":"The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects","volume":"171","author":"Rhee","year":"2014","journal-title":"Eur J Endocrinol."},{"key":"2022061616000036200_CIT0047","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1210\/jc.2010-2178","article-title":"Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as \u201cisoglycemic\u201d intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes","volume":"96","author":"Vardarli","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"2022061616000036200_CIT0048","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2337\/db13-0805","article-title":"Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and \u201cisoglycemic\u201d intravenous glucose","volume":"63","author":"Vardarli","year":"2014","journal-title":"Diabetes."},{"key":"2022061616000036200_CIT0049","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2337\/db09-1169","article-title":"TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action","volume":"59","author":"Villareal","year":"2010","journal-title":"Diabetes."},{"key":"2022061616000036200_CIT0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw."},{"key":"2022061616000036200_CIT0051","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/sim.4451","article-title":"Higher-order likelihood inference in meta-analysis and meta-regression","volume":"31","author":"Guolo","year":"2012","journal-title":"Stat Med."},{"key":"2022061616000036200_CIT0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v050.i07","article-title":"The R package metaLik for likelihood inference in meta-analysis","volume":"50","author":"Guolo","year":"2012","journal-title":"J Stat Softw."},{"key":"2022061616000036200_CIT0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v034.i12","article-title":"glmulti: an R package for easy automated model selection with (generalized) linear models","volume":"34","author":"Calcagno","year":"2010","journal-title":"J Stat Softw."},{"key":"2022061616000036200_CIT0054","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2337\/db09-1899","article-title":"Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?","volume":"59","author":"Meier","year":"2010","journal-title":"Diabetes."},{"key":"2022061616000036200_CIT0055","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1210\/jc.2012-1205","article-title":"Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes","volume":"97","author":"Muscelli","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2022061616000036200_CIT0056","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.numecd.2017.10.006","article-title":"Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response","volume":"27","author":"Tura","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"2022061616000036200_CIT0057","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2337\/dc21-0545","article-title":"New insights on the interactions between insulin clearance and the main glucose homeostasis mechanisms","volume":"44","author":"Bizzotto","year":"2021","journal-title":"Diabetes Care."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac213\/43513980\/dgac213.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/7\/2092\/44110378\/dgac213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/7\/2092\/44110378\/dgac213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T16:00:50Z","timestamp":1655395250000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/7\/2092\/6565992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":57,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4,9]]},"published-print":{"date-parts":[[2022,6,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac213","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,4,9]]}}}